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slanDCs selectively accumulate in
carcinoma-draining lymph nodes and
marginate metastatic cells
William Vermi1,2, Alessandra Micheletti3,*, Silvia Lonardi1,*, Claudio Costantini3, Federica Calzetti3,
Riccardo Nascimbeni1, Mattia Bugatti1, Manuela Codazzi1, Patrick C. Pinter4, Knut Scha¨kel5,
Nicola Tamassia3 & Marco A. Cassatella3
Dendritic cells (DCs) initiate adaptive immune responses to cancer cells by activating naive
T lymphocytes. 6-sulfo LacNAcþ DCs (slanDCs) represent a distinct population of circu-
lating and tissue proinﬂammatory DCs, whose role in cancer immune surveillance is
unknown. Herein, by screening a large set of clinical samples, we demonstrate accumulation
of slanDCs in metastatic tumour-draining lymph nodes (M-TDLN) from carcinoma patients.
Remarkably, slanDCs are absent at the primary carcinoma site, while their selective nodal
recruitment follows the arrival of cancer cells to M-TDLN. slanDCs surround metastatic
carcinoma deposits in close proximity to dead cells and efﬁciently phagocytose tumour cells.
In colon carcinoma patients, the contingent of circulating slanDCs remains intact and
competent in terms of IL-12p70 and tumour necrosis factor alpha production, induction of
T-cell proliferation and migratory capacity to a set of chemokines produced in M-TDLN.
We conclude that activated slanDCs represent previously unrecognized players of nodal
immune responses to cancer cells.
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D
endritic cells (DCs) consist of a heterogeneous population
of circulating and tissue leukocytes1,2 capable of directing
adaptive T-cell immune responses to cancer cells3. DCs
promote protective immunity by capturing antigens at the
primary tumour site, migrating to lymph nodes via lymphatic
vessels, and ultimately presenting these tumour-derived antigens
to nodal naive T cells1,2,4. Alternatively, antigens can enter the
lymph, reach the nodal marginal sinus and therein be captured
and processed by nodal resident antigen-presenting cells5. In a
clinically apparent tumour mass, however, the spontaneous
immune response regularly fails to achieve a complete
elimination of cancer cells, with DCs losing their adjuvant
function and, similar to many other immune and non-immune
cells, acquiring a tumour-promoting programme that sustains
tumour escape4,6–8.
In human blood, DCs are classically divided into three major
subtypes: CD303þ plasmacytoid DCs (pDCs) and two CD11cþ
myeloid DC (mDC) subsets, namely a major subset represented
by CD1cþ (BDCA1þ ) DCs and a discrete CD141þ (BDCA3þ )/
CLEC9Aþ DC subset9,10. Recently, a distinct population of
peripheral and tissue proinﬂammatory DCs has been designated
as 6-sulfo LacNAcþ DCs (‘slanDCs’) based on its selective
expression of the 6-sulfo LacNAc (slan) residue on the P-selectin
glycoprotein ligand 1 membrane molecule, also known as M-DC8
(ref. 11). Circulating slanDCs represent 0.6–2% of peripheral
blood mononuclear cells (PBMC) and are phenotypically distinct
from pDCs and mDCs. They are, in fact, CD11cþ /C3aRþ /
CD45RAþ /6-sulfo LacNAcþ and also characterized by a marked
expression of CD16, as well as a very low expression of CD14
(ref. 12). Functionally, slanDCs stand out for their remarkable
capacity to produce tumour necrosis factor alpha (TNFa) and
IL-12p70 upon stimulation with discrete toll-like receptor
ligands13,14. In addition, they are potent inducers of primary
antigen-speciﬁc T-cell responses in vitro11, and show a superior
programming of Th1/Th17 cell polarization as compared with
classical CD1cþ DCs14. Furthermore, slanDCs induce in vitro
tumour-speciﬁc cytotoxic T cells and strongly promote natural
killer (NK) cell proliferation, NK cytotoxic activity and, in
cooperation with neutrophils, NK-derived interferon-gamma
(IFNg) production15–17. However, since the identiﬁcation and
functional analysis of human slanDCs in cancer patients has
not been explored yet, in this study, we investigated such an
issue.
As a result, we uncover slanDCs as previously unidentiﬁed
antigen-presenting cells that selectively accumulate in metastatic
tumour-draining lymph nodes (M-TDLN) from carcinoma
patients, where they likely participate in the organization of the
nodal immune response.
Results
slanDCs populate the mucosal-associated lymphoid tissues. In
preliminary experiments, we comprehensively characterized the
systemic distribution of human slanDCs under homoeostatic
conditions. Human slanDCs can be speciﬁcally identiﬁed and
monitored in formalin-ﬁxed parafﬁn-embedded (FFPE) tissue
sections by staining with DD2 and DD1 mAbs17 that, similarly to
the M-DC8 mAbs, recognize slan/M-DC8 (ref. 11). Tissue
slanDCs were originally identiﬁed as M-DC8þ cells in the
T-cell area of human tonsils by immunohistochemistry of frozen
samples18. By using either DD2 or DD1, we conﬁrmed that
slanDCs are regularly found in nasopharyngeal (5/5 of our cases)
and palatine (20/20 of our cases) tonsils, being particularly
abundant in the crypts, where they strictly intermingle with
epithelial cells (Fig. 1a). No reactivity in tonsils was detected by
using isotype control antibodies (Supplementary Fig. S1a,b).
More rarely, slanDCs were also found in the interfollicular area,
whereas no DD2þ cells were found in the surface epithelium
(Supplementary Fig. S1c,d). At high power view (Fig. 1b), the
morphology of tonsil slanDCs appear heterogeneous, encompass-
ing a dominant fraction of large cells with stellate morphology
admixed to a minor cellular fraction of smaller cells with round-
to-oval shape. In addition, most slanDCs were non-proliferating
based on Ki-67 expression (Supplementary Fig. S1e,f). By
analysing single-cell suspensions from human reactive tonsils,
using a ﬂow cytometry strategy recently reported19, we could
conﬁrm that among the various HLA-DRþ /CD11cþ DCs,
slanDCs are clearly distinct from CD1cþ (BDCA1þ ) DCs,
CD141þ (BDCA3þ )/CLEC9Aþ DCs and CD14high macro-
phages (Fig. 1c–e).
By using an extensive panel of markers recognizing other tissue
DCs and macrophages on FFPE sections, we found (either by
immunohistochemistry or immunoﬂuorescence) that a signiﬁcant
fraction of tonsil slanDCs co-express CD11c and CD68 (by using
either KP1 or PG-M1 mAbs), and less frequently Fascin, nuclear
S100 protein, CD14, lysozyme (LYS), CD16, CD40, myeloperox-
idase, neutrophil elastase and factor XIIIa (Fig. 1f–m and
Supplementary Fig. S2), but are largely negative for markers
restricted to pDCs (such as CD303 and CD123), Langerhans cells
(such as CD1a and CD207), mature DCs (such as CD83 and
CD208) and macrophages (such as CD163, CD11b and CD169).
Positivity for a number of tonsil slanDC markers, including
membrane M-DC8, were substantially conﬁrmed on cytospin
preparations of slanDCs puriﬁed from peripheral blood
(Fig. 2a–f). On the other hand, ﬂow cytometry studies of tonsil
cell suspensions conﬁrmed the lack of CD11b expression by tonsil
slanDCs as opposed to the circulating counterpart11, suggesting
that slanDCs downregulate CD11b once migrated into inﬂamed
tonsils/tissues.
DD2 or DD1 mAbs, on sections, also recognized slanDCs in
the dome region of Peyer’s patches (Fig. 2g), but failed to identify
sizeable numbers of slanDCs in other lymphoid organs such as
the spleen, thymus and bone marrow. In most of the lymph nodes
showing histology of nonspeciﬁc lymphadenitis (10/12 of cases),
slanDCs were very rare with the exception of two cases
characterized by a prominent follicular hyperplasia, in which
we could detect CD68þ /CD11cþ /DD2þ slanDCs in the extra-
follicular area surrounding high endothelial venules (HEV). We
also conﬁrmed that DD2 does not recognize nodal CD303þ
pDCs and CD1aþS100þ interdigitating DCs (iDCs), as indicated
by double immunohistochemistry of sections from different
forms of pDC- and iDC-rich lymphadenitis (Fig. 2h,i). Finally,
Langerhans cells, interstitial DC (for example, dermal DCs), as
well as different forms of specialized macrophages (for example,
CD163þ alveolar macrophages, CD163þ Kupffer cells as well as
Iba1þ microglia) were neither recognized by DD2 nor by DD1
mAbs (Fig. 2j–o). Altogether, these data conﬁrm that DD2 and
DD1 mAbs speciﬁcally and uniquely recognize tissue slanDCs in
FFPE13, and establish that they are particularly abundant at the
lymphoid–epithelial interface of mucosal-associated lymphoid
tissues.
slanDCs accumulate in M-TDLN of carcinoma patients.
slanDCs are known to accumulate in peripheral tissues during
chronic and autoimmune inﬂammatory disorders, such as
Crohn’s disease, rheumatoid arthritis and psoriasis13,14,17. Given
their potent proinﬂammatory properties and propensity to tightly
interact with epithelial cells, we posited that slanDCs could
represent a hitherto unrecognized cellular component of the
carcinoma microenvironment. To test this hypothesis, we used
immunohistochemistry for M-DC8, as this marker is stable in
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Figure 1 | Distribution and phenotype of slanDCs in human tonsils. Sections are from representative FFPE human tonsils and are stained as indicated by
labels (CKP, pan-cytokeratin; LYS, lysozyme). (a) DD2þ slanDCs surround the CKPþ epithelium of tonsil crypts and mostly appear as large and stellate
cells (b) (n¼ 10). (c) Flow cytometry analysis was performed on live CD45þ/HLA-DRþ -singlet cells from CD3þ/CD19þ - depleted tonsil cell
suspensions. The panel shows the gating strategy used to identify CD141þDCs (blue gate), CD1cþDCs (orange gate), CD14high MF (grey gate) and
slanDCs (purple gate), within the HLA-DRþ/CD11cþ cells. By the same strategy, pDCs were identiﬁed within the HLA-DRþ/CD11c cells (green gate).
A representative experiment out of three ones performed with similar results is shown. (d) Bar graph shows the percentage of each DC subset and
macrophages within the HLA-DRþ cells (mean±s.d.; n¼ 5). (e) The histogram shows the relative expression of M-DC8 by each DC and MF populations.
Data are representative of similar results obtained from ﬁve tonsil preparations. (f–m) Panels show representative DD2þ slanDCs co-stained with
antibodies towards a set of markers (n¼ 10), as labeled. Sections are counterstained with Meyer’s haematoxylin. Original magniﬁcations: 40X (a, scale bar,
500mm); 400X (b,f–m, scale bar, 50mm).
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slanDCs and apparently not inducible by tumour-cell-
conditioned media in other monocyte/DC populations
(Supplementary Fig. S3). We initially screened reactivity for
DD2 and DD1 clones on three distinct multi-tumour tissue
microarrays (TMA) containing a total of 126 primary carcinomas
(PCs) from different organs (Supplementary Table S1). As
expected, the large majority of the samples in the TMA showed
inﬁltration by tumour-associated macrophages and DCs, as
conﬁrmed by stains for CD68 (100% of the cases), CD11c
(99.2%), CD163 (the marker for M2-polarized macrophages,
99.2%) and CD1a (49.6%) (Fig. 3a and Supplementary Fig. S4).
In contrast, DD2þ /DD1þ slanDCs were rarely found (1.7%)
(Fig. 3a and Supplementary Fig. S4).
Given the low occurrence of slanDCs within PC, we then
extended our analysis to metastatic tumour-draining lymph
nodes (M-TDLN). Strikingly, slanDCs were numerous and easily
detectable in 36/80 (45% of the cases) M-TDLN from carcinoma












Figure 2 | Phenotype of slanDCs in peripheral blood and human tissues. (a–f) Panels are from cytospin preparations of freshly puriﬁed peripheral
blood slanDCs, stained as labelled (LYS, lysozyme). Positivity is observed for all markers tested (n¼ 5). (g–o) Sections are from human small
bowel (g), reactive lymph node (h,i), normal lung (j,m), liver (k,n) and brain (l,o), and stained as labelled. M-DC8þ slanDCs are numerous in Peyer’s
patches (g), while in reactive lymph nodes CD303þ pDCs (h) and CD1aþ iDCs (i) are negative for M-DC8. On serial sections, CD163þ alveolar
macrophages (j,m), CD163þ Kupffer cells (k,n) and Iba1þ microglia (l,o) do not co-express M-DC8 (by DD2 staining). Sections are counterstained
with Meyer’s haematoxylin. LF, lymphoid follicle. Magniﬁcation: 600X (a–f; scale bar, 33 mm), 100 (g; scale bar, 200mm), 400X (h,i; scale bar, 50mm)
and 200X (j–o; scale bar, 100 mm).
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slanDCs were very rare or undetectable (Supplementary Table S2).
By cell counting, the density of slanDCs in M-TDLN was
283±96mm2 (n¼ 17). Of note, slanDCs were very rare or
undetectable in all 155 non-metastatic TDLN draining breast
carcinoma (n¼ 82), head and neck squamous cell carcinoma
(n¼ 30), colon carcinoma (n¼ 28) and cutaneous melanoma
(n¼ 15) (Fig. 4a–d). When the cohort of M-TDLN was
segregated based on the site of origin of the PC, slanDC
accumulation was found to be particularly frequent in M-TDLN
draining carcinomas from the genital (67% of the cases),
gastrointestinal (59% of the cases) and urinary tract (57% of
the cases) (Figs 3b and 4e–n,q,r). The occurrence of slanDCs did
not correlate with a speciﬁc subtype of the PC (Supplementary
































































Figure 3 | Tumour-associated slanDCs are detectable only in M-TDLN. (a) Graph shows the frequency of carcinoma cases containing DC subsets
and macrophages. Data have been obtained by scoring multi-tumour TMA sections stained for CD68, CD11c, CD163, CD1a and DD2 (n¼ 3).
(b) Graph shows the frequency of M-TDLN cases from different primary tumours containing slanDCs (GE, genital; GI, gastrointestinal; UR, urinary;
LU, lung; H&N, head and neck; BR, breast; SK, skin). Data have been obtained by analysing a cohort of eighty M-TDLN on sections stained for DD2.
(c–h) Sections are from M-TDLN stained as indicated. In M-TDLN, numerous slanDCs commonly line the nodal metastasis (c), while in cases with
low tumour burden (d) slanDCs are found in close contact with dispersed single tumour cells. Double immunohistochemistry illustrates co-expression
of CD68 (e) and CD11c (f) by DD2þ slanDCs. (g,h) Comparative analysis of a slanDC-rich M-TDLN (g) with its matched primary carcinoma (h), the latter
completely devoid of slanDCs in the surrounding tumour stroma. Sections are counterstained with Meyer’s haematoxylin. Original magniﬁcations:
40X (c, scale bar, 500mm); 600X (d–f, scale bar, 33 mm); 100X (g,h, scale bar, 200 micron). T, tumour cells.
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perimeter of metastatic nests within most M-TDLN, but only
rarely inﬁltrated the tumour nests themselves (Figs 3c, and
4e–h,m,n). Even among M-TDLN cases containing rare slanDCs,
the latter were selectively localized in close proximity to
carcinoma cells, implying a tropism for transformed epithelial
cells (Fig. 3d). Similar to slanDCs found in tonsils (Fig. 1f,g),
slanDCs within M-TDLN co-stained for CD68 and CD11c
(Fig. 3e,f) and were non-proliferating based on the lack of Ki-67
reactivity (Supplementary Fig. S1g,h).
Benign epithelial inclusions can be found in lymph nodes
draining multiple body sites20,21. We asked if slanDC presence in
LNs was speciﬁc to M-TDLN or whether slanDCs were normally
present in LNs containing epithelial cells, even in the absence of
malignancy. To this end, 13 non-inﬂamed, salivary gland DLN
containing benign epithelial inclusions were examined, and 12/13
were found to be devoid of slanDCs (Fig. 4o,p,s,t), suggesting that
nodal inﬂammation is required for slanDCs to gain access to the
lymph node parenchyma. To further conﬁrm the selective nodal
tropism of slanDCs in carcinoma patients, multiple tissue blocks
obtained from matched PC were analysed in a subgroup of 14
M-TDLN highly enriched in slanDC content. Expectedly,
although the PC contained high numbers of tumour-associated
DCs and macrophages, as proved by CD68, CD163, CD303,
CD11c and CD1a staining, the large majority of them
(12/14, 86.8%) were completely devoid of slanDCs, as shown by
the comparative analysis of slanDC-rich M-TDLN with matched
PC (Fig. 3g,h). Finally, slanDC inﬁltration was detected only
infrequently in carcinoma distal metastases (3/52; 5.7% of the
cases) (Fig. 4u–x). Collectively, these data suggest that slanDCs
represent a new subset of distinct tumour-associated immune
cells that are selectively recruited to M-TDLN.
M-TDLN slanDCs are distinct from other M-TDLN DCs. The
distribution of slanDCs in M-TDLN was then compared with that
of other canonical lymph node-resident DCs, namely pDCs and
iDCs. In fact, within reactive human lymph nodes, including
M-TDLN, CD303þ pDCs are selectively found in the extra-
nodular compartment surrounding HEV22,23, whereas iDCs
represent Langerhans-derived DCs, identiﬁable by the
expression of CD1a, S100 protein and CD207 in the expanded
paracortex of dermatopathic lymphadenitis24. In the 14 cases of
slanDC-rich M-TDLN that we could test, CD303þ pDCs and
CD1aþ iDCs were expanded in their respective compartments
(Fig. 5a,b). In addition, CD1aþ DCs were also found within
the tumour nests, whereas pDCs occasionally surrounded
the nodal metastasis (Fig. 5a,b). In striking contrast, slanDCs
were selectively found at the expansion front of the nodal
metastatic deposit (Figs 5c and 4e–h,m,n), almost exclusively
in contact with carcinoma cells. When tested by double
immunohistochemistry, we found that both slanDCs and pDCs
in M-TDLN were negative for CD83 and CD208/DC-LAMP
(Fig. 5d,e and Supplementary Fig. S5a,b), consistent with a mostly
immature phenotype, whereas a fraction of CD1aþ iDCs were
co-stained with both maturation markers (Fig. 5f and
Supplementary Fig. S5c). On the other hand, slanDCs stained
positive for HLA class II and CD40 molecules (Fig. 5g,h). In
addition, a fraction of M-TDLN slanDCs (37±8%, n¼ 4) also
co-stained for cytoplasmic TNFa (Fig. 5i). This set of data
suggests that slanDCs behave differently compared with other
nodal DCs, as once recruited into the M-TDLN, they are partially
activated and selectively localize adjacent to cancer cells.
slanDC accumulation in TDLN represents an early event.
Subsequently, we took advantage of the sentinel lymph node
(SLN) procedure to correlate slanDC nodal inﬁltration with the
occurrence and progression of cancer cell colonization in TDLN.
SLN biopsy is based on the assumption that cancer cells from a
PC reach the SLN ﬁrst, which can be accurately identiﬁed and
then removed. In breast cancer, SLN biopsy represents a standard
of care for nodal staging and might indicate a complete axillary
lymph node dissection (ALND). Thus, for our analysis, we used
51 metastatic SLN (M-SLN) samples from patients with breast
carcinoma. The presence of slanDCs in this cohort was docu-
mented in 17/51M-SLN (33.3% of the cases) (Fig. 6a), a similar
frequency to what was observed in non-sentinel M-TDLN
draining breast cancer (NSLN, 33.3% of the cases) (Fig. 6a).
We then veriﬁed whether slanDC accumulation anticipates nodal
metastasis and prepares tumour cell niches25. To this end,
we analysed a subgroup of 22 cases of non-metastatic SLN
(NM-SLN) and, remarkably, we found that only one NM-SLN
case (1/22 (4.5%)) already contained slanDCs (Fig. 6a). Finally,
we tested whether the presence of slanDCs in M-SLN could
predict the ALND status in term of cancer cell colonization.
We found that slanDC occurrence in M-SLN was not signiﬁcantly
associated with the ALND status (11/33 (33.3%) for tumour-
negative ALND versus 4/18 (22.2%) for tumour-positive ALND,
P¼ 0.75) (Fig. 6b–f). Taken together, data suggest that, at
least in human breast cancer, slanDC nodal accumulation in
TDLN, although representing an early event (for example,
colonization of the SLN), it is strictly coupled to nodal cancer
cell colonization and cannot predict cancer dissemination to
other nodes.
slanDCs are distinct from Tie2-expressing monocytes. Our
ﬁndings indicate that slanDCs are distinct from other tumour-
associated DCs and macrophages in terms of distribution and
location within the cancerous tissues. slanDCs are known to
partially overlap12 with the heterogeneous population of the
CD16þ monocytes among PBMC (plots illustrating the gating
strategy to identify the non-classical (CD14dim/CD16þ ),
intermediate (CD14þ /CD16þ ) and classical (CD14þ /CD16 )
monocyte subsets, as well as slanDCs within the CD14dim/
CD16þ monocytes are displayed in Fig. 7a) that have been also
shown to include the Tie2-expressing monocytes (known as
TEMs)26. The latter cells generate a perivascular cell population
endowed with a prominent pro-angiogenic potential in a variety
of human and mouse primary tumours, including human
carcinomas26,27. However, even though circulating slanDCs,
similarly to TEMs26, stain positively for CD16, CD33, CD13,
CD11b and CD11c, but negatively for CCR2 and CD62L (ref. 11),
they are distinct from TEMs as demonstrated by multiple
evidence. First, circulating slanDCs are negative for Tie2 expres-
sion, unlike the CD14þ /CD16þ monocytes28,29 as revealed by
ﬂow cytometry (using two different anti-Tie2 mAbs) (Fig. 7b,c).
Second, lack of Tie2 expression by slanDCs was also conﬁrmed by
quantitative polymerase chain reaction (Supplementary Fig. S6a),
and immunoblotting analysis (using two additional anti-Tie2
mAbs) (Supplementary Fig. S6b). Third, Tie2 mAbs failed to
recognize any cells in the crypts of slanDC-rich tonsillar sections,
where instead they stained only endothelial cells (Fig. 7d). Fourth,
tumour-associated slanDCs are not perivascular and are only
found in M-TDLN and not in PC, at variance with known
patterns of TEM localization26. Finally, tumour-associated
slanDCs do not express Tie2, as proven by immunohisto-
chemical staining using an anti-Tie2 mAb suitable for FFPE
tissues (Fig. 7e).
slanDCs contact innate and adaptive immune cells in M-TDLN.
Noteworthy, based on quantiﬁcation performed on double-stained
sections, we found that a variable fraction of slanDCs is in contact
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either with CD56þ NK cells (10±6.5%, n¼ 5) or CD66bþ
neutrophils (14±11%) in M-TDLN (Fig. 8a,b), consistent with the
establishment of a potential functional network among slanDCs,
neutrophils and NK cells, as previously shown17. Most slanDCs
(91±4%) regularly interact with CD3þ -T cells, particularly
CD4þ -T cells (Fig. 8c,d). As quantiﬁed by capturing identical























a b c d
e f g h
i j k l
m n o p
q r s t
u v w x
Figure 4 | slanDCs in human TDLN and carcinoma distant metastasis. Sections are from representative NM-TDLN (a–d; n¼ 155) and M-TDLN (e–n,q–r;
n¼ 80), stained using the DD2 clone. slanDCs are virtually undetectable in NM-TDLN draining breast carcinoma (a), head and neck squamous cell
carcinoma (b), colon carcinoma (c) and cutaneous melanoma (d). Examples of M-TDLN draining different primary sites including genital (GE; e,i),
gastrointestinal (GI; f,j), urinary (UR; g,k), lung (LU; h,l), head and neck (H&N; m,q) and skin (SK; n,r), with (e–h and m,n) or without (i–l and q,r)
slanDCs. (o,p,s,t) Sections are from salivary glands (SG)-draining LNs containing CKPþ (blue) benign epithelial inclusions and co-stained for
M-DC8 (brown); DD2 reactivity is limited to HEV. (u–x) Sections are from a set of representative carcinoma metastases (n¼ 52) from different
primary sites (indicate by labels) to the liver (u), brain (v), pleura (w) and lung (x); M-DC8þ slanDCs are detectable only in a case with dense
leukocyte inﬁltration (u). T, tumour cells. Sections were counterstained with Meyer’s haematoxylin. Original magniﬁcations: 100X (a–d,u–x;
scale bar, 200mm) and 200X (e–t; scale bar, 100 mm).
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microscopic areas of digitalized slides obtained from serial sections
of M-TDLN (Supplementary Fig. S7), T lymphocytes in slanDC-
rich areas included a signiﬁcantly dominant GATA3þ population
admixed to more rare T-Betþ and Foxp3þ regulatory T cells
(Fig. 8e; Supplementary Table S3). A similar pattern was observed
in the group of M-TDLN lacking slanDCs (Fig. 8e; Supplementary
Table S3), indicating that a Th2-type immune response regularly
prevails in M-TDLN. Altogether, these ﬁndings indicate that, in
advanced stage cancer (for example, with nodal spread), slanDCs
interact with other immune cells in a dominant Th2-polarized
nodal microenvironment.
slanDCs from CCR patients are functionally competent. By
screening a set of slanDCþ M-TDLN using active caspase 3
staining, we found that cell death is abundant and very common
particularly within and around metastatic tumour nests
(Supplementary Fig. S8). Signiﬁcantly, a fraction of M-TDLN-
associated slanDCs (16±9%, n¼ 5) was found in close proximity
to apoptotic cells/bodies, as revealed on double staining for active
caspase 3 and DD2 (Fig. 8f; insert). Thereby, we tested whether
slanDCs could phagocytose apoptotic tumour cells in vitro.
To this end, we co-incubated freshly isolated slanDCs with
apoptotic cells previously prepared from a panel of colon
carcinoma cell lines, namely HT29 and SW480 cells from
primary tumours, and SW620 and LOVO cells from metastatic
lymph nodes. As shown in Fig. 9a, slanDCs variably, but very
efﬁciently, phagocytosed tumour cell-derived apoptotic bodies,
displaying similar or -for SW480 cell line- signiﬁcantly higher
phagocytic capacity than CD1cþ DCs from the same healthy
donors. Under these experimental conditions, CD14þ monocytes
and pDCs displayed, respectively, the highest and the lowest
phagocytosing capacity (Fig. 9a). We also observed that the
uptake of tumour-cell-derived apoptotic bodies by slanDCs
is Dectin-1/CLEC7A- and CD18-independent, and that
IFNg- activated slanDCs cultured with ﬂuorescent-labelled, alive
HT29 cells contained intracellular apoptotic bodies likely derived
from the slanDC-mediated killing of HT29 cells, as previously
shown16.
Circulating mDCs and pDCs from cancer patients are
frequently reduced in number and functionally defective30–34.
Recent works have proved the prognostic signiﬁcance of the
immune response to colon carcinomas (CCR)35,36. By testing a
cohort of CCR patients (details are reported in Supplementary
Table S4), we found that the absolute number of peripheral






















Figure 5 | Comparative analysis of tumour-associated DCs in M-TDLN. (a–i) Sections are from M-TDLN and stained as indicated. In this
representative case (n¼ 5), CD303þ pDCs (a) and CD1aþ iDCs (b) are mostly expanded in their own nodal compartments, with iDCs also inﬁltrating
the tumour (T) nests, whereas DD2þ slanDCs are found at the periphery of the tumour nodule (c). As shown by double staining, slanDCs are negative
for CD83 (d) and CD208/DC-LAMP (e), at variance with CD1aþ iDCs (f), but co-express HLA-II molecule (g), CD40 (h) and TNFa (i). Sections are
counterstained with Meyer’s haematoxylin (a–f and h,i) and DAPI (g). Original magniﬁcations: 100X (a–c, scale bar, 200mm); 200X (d,e, scale bar,
100mm); 400X (f, scale bar, 50mm); 600X (g–i, scale bar, 33mm).
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both younger- or age-matched healthy donors (Fig. 9b). By
contrast, pDCs from the same patient cohort were signiﬁcantly
reduced in number, not only in an age-dependent but also in
a cancer-related manner (Fig. 9c), in line with published
observations31,34,37–39. Concomitantly, we also found that either
the ability to ingest tumour cell-derived apoptotic bodies
(Fig. 9a), or the capacity to produce and release TNFa and
IL-12p70 in response to, respectively, lipopolysaccharide (LPS)
and LPS plus IFNg (Fig. 9d,e), was fully retained by CCR
slanDCs. By contrast, the capacity of CCR-derived pDCs to
produce IFNa upon CpG stimulation was partially defective
(Fig. 9f), as largely documented in patients with other carcinoma
types34,40,41. Signiﬁcantly, number and function (for example,
cytokine production) of the slanDC contingent was maintained
even in advanced disease stages (Fig. 9b,d,e). Moreover, slanDCs
from CCR patients retained the ability to stimulate T-cell
proliferation in both autologous (Fig. 9g) and allogeneic settings
(Fig. 9h). Supernatants harvested from colon carcinoma
metastatic cell lines (such as SW620, LOVO and COLO-678)
inﬂuenced neither the capacity of IFNg plus LPS-activated
slanDCs to produce TNFa or IL-12p70, nor their survival rate
(Supplementary Fig. S9).
Finally, to identify potential mediators responsible for slanDC
migration to M-TDLN, we initially tested the expression levels of
a set of chemotactic receptors by slanDCs. As a result, we
uncovered that slanDCs from CCR subjects displayed slightly
higher, but not statistically signiﬁcant, levels of surface CXCR4
than control slanDCs, in contrast to surface CX3CR1 and C5aR,
which were expressed at identical amounts on the two slanDC
populations (Fig. 10a,b). As expected14, CCR2, CCR3, CCR5 and
CXCR3 were expressed neither in slanDCs from healthy donors
nor in slanDCs from CCR subjects. Importantly, chemotaxis
induced by CXCR4, CX3CR1 or C5aR ligands was substantially
equivalent in slanDCs derived from CCR subjects and healthy
controls (Fig. 10c). These ﬁndings are relevant, as the ligands for
CXCR4, CX3CR1 and C5aR, respectively CXCL12/SDF-1,
CX3CL1/Fractalkine and C5a, are strongly expressed in
M-TDLN where slanDCs are found (Fig. 10d–i). Speciﬁcally,
CXCL12/SDF-1 and CX3CL1/Fractalkine were detected primarily





























































Figure 6 | slanDCs in breast cancer TDLN. (a) Graph illustrates the frequency of slanDCs in non-sentinel M-TDLN from the entire cohort (NSLN; n¼ 80),
metastatic breast cancer SLN (M-SLN; n¼ 51) and non-metastatic breast cancer SLN (NM-SLN; n¼ 22). (b) Graph illustrates the frequency of slanDCs in
M-SLN with (ALNDþ) or without (ALND) metastasis in the ALND (***Po0.0001; P40.05 is nonsigniﬁcant (NS) by Fisher’s test). (c–f) Sections are
from a representative M-SLN and matched ALND as indicated, and stained for DD2 (c,e) and H&E (d,f). T, tumour. Sections are counterstained with
Meyer’s haematoxylin (c,e). Original magniﬁcations: 200X (c,e, scale bar,100mm) and 100X (d,f, scale bar, 200mm).
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of CXCL12/SDF-1, in the HEV endothelium. In contrast, C5a
was detected in nodal macrophages and other CD11cþ cells
(Fig. 10f; insert). Remarkably, a strong CXCL12/SDF-1 and
CX3CL1/Fractalkine signal in M-TDLN was evident also in
tumour cells adjacent to slanDCs (Fig. 10g,h). However, when
tested in TMA, as well as in a set of eight carcinoma cases for
which matched PC and M-TDLN were available, we detected
similar CXCL12, CX3CL1 and C5a expression levels also in PC.
Altogether, these data indicate that the expansion of fully
competent circulating slanDCs in CCR patients might signiﬁ-
cantly contribute to kill and capture tumour cells, efﬁciently



































































































































































Figure 7 | Circulating and tissue slanDCs in tonsils and M-TDLN do not express Tie2. (a) Gating strategy used to identify monocyte subpopulations
(on the basis of CD14 and CD16 expression) and slanDCs (on the basis of M-DC8 staining within the CD14dim/CD16þ subset) in PBMC. (b,c) HUVEC
and slanDCs or CD14þ/CD16þ monocytes within PBMC were analysed for Tie2 expression by ﬂow cytometry using two different anti-human Tie2
monoclonal antibodies (Tie2#1, a PE anti-Tie2 mouse IgG1 from R&D in b; Tie2#2, a PE anti-Tie2 mouse IgG1 from BioLegend in c). Bar graphs reporting
the mean±s.d. (n¼ 5–10) are also shown. ***Po0.001; **Po0.01; *Po0.05, by ANOVA. Representative histograms from ﬁve experiments with
similar results are shown. (d,e) Sections are from a frozen tonsil (d) and ﬁxed M-TDLN (e), stained as indicated and counterstained with Meyer’s
haematoxylin. Tie2 staining with two different antibodies fails to recognize slanDCs in M-TDLN (e), while it is very intense in vessel endothelium (d,e).
T, tumour cells. Original magniﬁcations: 200X (d, scale bar, 100 mm) and 400X (e, scale bar, 50mm).
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and IL-12p70. Our data also imply that C5a, CX3CL1/Fractalkine
and CXCL12/SDF-1, which are abundantly produced by
carcinoma cells and nodal stromal cells, participate to the speciﬁc
homing of slanDCs to inﬂamed M-TDLN.
Discussion
Although slanDCs represent the most abundant CD11cþ mDCs
in humans11, and characteristically display efﬁcient proinﬂamma-
tory properties11,13,15, their role in cancer immunoediting has
never been explored, likely because their murine counterpart has
not been identiﬁed yet. Therefore, in this study, we made a
systematic characterization of slanDCs in human cancers and, as
a result, we could identify slanDCs as new players in cancer
immunity for their direct participation in the organization of
nodal immune responses to transformed epithelial cells. We, in
fact, found that slanDCs distinctively home to M-TDLN in
patients affected by different forms of carcinomas. Remarkably,
slanDCs are absent in PC, while their nodal recruitment follows
the arrival of carcinoma cells to M-TDLN, as indicated by the
analysis of SLNs from breast cancer patients. The complete
absence of slanDCs in the PC microenvironment was conﬁrmed
by analysing multiple sections of different PC tumour blocks with
their matched M-TDLN, the latter of which contained high
numbers of slanDCs. Of note, the majority of PC analysed in this
study contained sizeable numbers of macrophages and other DC
subtypes. Moreover, based on a series of investigations on their
distribution and phenotype in vivo and in vitro, we were able to
demonstrate that slanDCs are clearly distinct from TEMs, a
subset of CD16þmonocytes that inﬁltrates PC and were recently
described to have pro-angiogenic activities26. Finally, slanDCs
behave differently compared with other nodal DCs in M-TDLN.
In fact, pDCs and iDCs were expanded in number in M-TDLN,
but maintained normal localization patterns, whereas slanDCs
were selectively juxtaposed with neoplastic nests at interfaces



















































Figure 8 | slanDCs interactions in Th2-polarized M-TDLN. (a–d) Double staining of sections from representative M-TDLN cases (n¼ 5) show that
slanDCs are in contact with CD56þ NK cells (a, arrow head), CD66bþ neutrophils (b, arrow heads) and CD3þ T cells (c, arrow head), the latter
population mainly represented by CD4þ T cells (d). Graph in (e) illustrates the quantitative analysis of cells expressing GATA3, T-Bet and Foxp3 in
M-TDLN (n¼ 10). (f with insert) slanDCs in M-TDLN were often found in close proximity to apoptotic cells/bodies as demonstrated by double staining
with active caspase 3 (n¼ 5). T, tumour cells. Sections are counterstained with Meyer’s haematoxylin. Original magniﬁcations: 600X (a–c, scale bar,
33mm); 400X (d, scale bar, 50mm) and 200X (f, scale bar, 100mm).
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establishes the uniqueness of carcinoma-associated slanDCs, and
illustrates that they are distinct from other major tumour-
associated leukocyte populations. Our data also suggest that
slanDC-homing to TDLN represents an early event that
speciﬁcally requires the co-occurrence of intranodal malignant
cell deposits.
Prior studies had shown that migration of circulating slanDCs
to tissues is guided by a set of chemotactic receptors including
CXCR4, CX3CR1 and C5aR11,14. Accordingly, we found that
CXCL12/SDF-1, CX3CL1/fractalkine and C5a, the ligands for
these receptors, are abundantly produced in M-TDLN, either by
lymph node cells (for example, HEV and stromal cells within the
interfollicular areas) or by carcinoma cells. Moreover, by studying
a cohort of CCR patients, we also demonstrate that CXCR4,
CX3CR1 and C5aR are normally expressed and functional in
circulating slanDCs. Noteworthy, CX3CL1/fractalkine is already
known to be speciﬁcally released by apoptotic cells to attract
leukocytes at the site of high-rate cell death42–44. However, the
fact that we found CXCL12/SDF-1, CX3CL1/fractalkine and C5a
expressed also in the PC (that do not contain slanDCs) clearly
indicates that recruitment of tumour-associated slanDCs require
a complex assembly of cellular and molecular components
governed by M-TDLN. We therefore postulate that a speciﬁc
set of adhesion molecules, likely expressed by HEV of inﬂamed
M-TDLN, might be crucial for the slanDC entry into the node.
We envisage that speciﬁc mechanisms could be also operative in
peripheral tissues of patients with autoimmune diseases, such as
Crohn’s disease, rheumatoid arthritis, psoriasis13,14,17 and lupus
erythematosus45, especially when slanDC inﬁltration is associated
to highly dense chronic inﬂammation, particularly in the form of
lymph follicle-like structures45.
Another novel ﬁnding highlighted in this study is the peculiar
localization of slanDCs in M-TDLN. We uncovered that slanDCs
are frequently poised at the interface between tumour nests and
lymphoid compartments, thus allowing a two-way direct inter-
action with both neoplastic cells and T cells. Although
presentation of tumour antigens by activated DCs is retained in
TDLN, most phagocytosis of tumour-derived antigens is exerted
by immature DCs in the PC. Prompted by the observations that
slanDCs display a phagocytic morphology (for example, large
cytoplasm containing intracellular debris), and contact apoptotic
caspase 3þ cells within metastatic nests, we analysed their ability
to phagocytose tumour cells in vitro. By using a panel of tumour
cell lines, we demonstrated that slanDCs displayed a similar or—
for some cell lines—a greater phagocytic capacity than classical
CD1cþ DCs from the same donor. Thus, the observed features of
slanDCs in M-TDLN (for example, localization close to
metastatic cells and phagocytic capacity) are of remarkable
biological and clinical relevance, as these ﬁndings imply that






























































































































































































































d e f g h
Figure 9 | Circulating slanDCs from CCR patients remain intact in terms of number and functional properties. (a) CCR-derived slanDCs and healthy
donor-derived slanDCs, CD1cþ DCs, pDCs, CD14þ monocytes were co-incubated for 18 h with apoptotic bodies derived from the indicated colon
adenocarcinoma cell lines at 1:3 ratio. Graph shows the net phagocytosis by each cell type calculated as it follows: % of phagocytosing cells at 37 C—% of
phagocytosing cells at 4 C (mean±s.d.; n¼4). Statistical signiﬁcance, by one-way ANOVA, is also indicated: a versus b, Po0.001; a versus c, Po0.05.
(b,c) Quantiﬁcation of circulating pDCs and slanDCs (mean±s.d.) in young (n¼ 18–23; age mean¼ 37; age range¼ 22–51) and old (n¼ 10–11; age
mean¼ 76; age range¼ 68–86) healthy donors, as well as CCR-bearing patients (n¼ 10–12; age mean¼ 73; age range¼ 53–86), further divided into two
groups according to their staging (I-IIs¼ stages I and II; III-IVs¼ stages III and IV). Symbols stand for: **Po0.01; *Po0.05, by Student’s t-test of unpaired
samples. (d–f) Graphs show the percentage (mean±s.d.) of TNFa- (d, n¼4–7), IL-12p70- (e, n¼ 3–4) producing slanDCs and IFNa-producing pDCs
(f, n¼ 3–4) by resting and stimulated PBMC from healthy donors or CCR-bearing patients. % of cytokine- secreting cells was calculated on live M-DC8þ
slanDC- or CD303þ pDC-gated cells. (g,h) Graphs report the percentage of proliferating autologous CD4þ T cells (g) or allogeneic CD4þ or CD8þ
T cells (h) cultured for 7 days with healthy donor- or CCR patient-derived slanDCs in the presence (g) or the absence (h) of tetanus toxoid (mean±s.d.;
n¼ 3–4).
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be directly presented to T cells by nearby slanDCs. This
hypothesis is consistent with recent observations, made by
intravital live imaging, clarifying that CD11cþ DCs poised at
the tumour margin constitutively ingest tumour-derived proteins
and present processed tumour antigens to reactive T cells46. In
addition, slanDC interactions with either NK cells or neutrophils
occurring in M-TDLN might further amplify nodal immune
responses, thus extending our previous observations on the
presence of slanDC/neutrophil/NK cell networks in inﬂamed
mucosal tissues17.
Remarkable results have been recently obtained by analysing
the signiﬁcance of the ‘immune contexture’ of primary tumours
in large cohorts of clinical samples47; however, it still remains
difﬁcult to establish the speciﬁc contribution of the innate
immune cell compartment to cancer immunity. In M-TDLN,
although we could detect some levels of activation of slanDCs
(by measuring TNFa and co-stimulatory molecule expression),
the analysis of nodal T-cell compartment showed a dominant
Th2-type polarization irrespective of the slanDC content. This
might reﬂect the prevalence of an immune suppressive envi-
ronment in advanced stage of cancer (for example, carcinomas
with nodal metastasis). Whatever the case is, circulating slanDCs
obtained from healthy donors, cultured in carcinoma cell-
conditioned medium, remain fully competent in terms of TNFa
and IL-12p70 production, and do not display an altered viability.
More importantly, by analysing circulating slanDCs from a
cohort of patients with advanced CCR, we found that the slanDC
compartment, unlike pDCs from the same patient cohort,
remains substantially intact in terms of number and responsive
















































































Figure 10 | Migratory properties by slanDCs from CCR patients and chemokine expression in M-TDLN. (a,b) Freshly isolated PBMC from healthy donors
and CCR patients were analysed for C5aR, CXCR4 and CX3CR1 expression on gated M-DC8þ slanDCs, by ﬂow cytometry. (a) Data for each chemokine
receptor are reported as mean ﬂuorescence intensity (after the subtraction of the mean ﬂuorescence intensity given by the correspondent isotype control
antibody, mean±s.d.; n¼6). (b) Representative histograms of CXCR4, CX3CR1 and C5aR expression by slanDCs from healthy donors and CCR patients
are shown. (c) Graph shows the percentage of migrating slanDCs towards CXCL12, CX3CL1 and C5a in chemotaxis assays (n¼4). (d–i) Sections from
slanDCs positive M-TDLN representative cases (n¼ 10) stained as indicated. CXCL12/SDF-1 and CX3CL1/Fractalkine are detected in tumour cells, nodal
stromal cells and, for CXCL12/SDF-1, also in HEV endothelium (serial sections d,e and g,h). C5a is mainly expressed by nodal stromal cells (f,i), some of
them expressing CD11c (blue, insert in f). T, tumour cells. Sections are counterstained with Meyer’s haematoxylin. Original magniﬁcations: 100X
(d,e, scale bar, 200mm); 200X (f–h, scale bar, 100mm) and 400X (i, scale bar, 50mm).
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induction of T-cell proliferation as well as gene expression proﬁle
by microarray analysis, even in advanced stage disease. Thus, in
contrast to other DC subsets7,34, our data suggest that circulating
slanDCs are not developmentally or functionally hijacked by
growing tumours and converted into immunosuppressive cells. If
so, we would further propose that, in advanced stage carcinoma,
when other circulating DCs are dysfunctional4,6–8 and migration
to draining lymph nodes is impaired48, or the source of tumour
antigens in the PC has been surgically removed, circulating
slanDCs might still represent a highly qualiﬁed second line
defence to be exploited.
Methods
Tissues. FFPE tissue blocks used for this study were retrieved from the tissue bank
of the Department of Pathology (Spedali Civili di Brescia, Brescia, Italy). Human
tissues included normal thymus, spleen and bone marrow, reactive lymphoid
organs (tonsils, lymph nodes, appendix) as well as normal non-lymphoid tissues
(ileum, colon, stomach, oesophagus, thyroid, salivary gland, oral mucosa, breast,
lung, brain, liver, pancreas, skin, kidney, ureter, bladder, testis, prostate, ovary,
endometrium, cervix). Pathological samples used for slanDC analysis included
multi-tumour TMA of mixed carcinomas ((Supplementary Table S1), see below for
technical details), sections of 10 primary cutaneous melanoma cases, 80 metastatic
tumour-draining lymph nodes (M-TDLN) (details are in Supplementary Table S2),
155 non-metastatic tumour-draining lymph nodes (non-metastatic TDLN), from
cutaneous melanoma, head and neck squamous cell carcinoma and colon carci-
noma, respectively, and a cohort of 52 distant metastasis to different organs (liver,
lung, brain, omentum, small intestine) derived from a set of PCs from different
sites (urinary tract, GI tract, breast, ovary, lung, head and neck and skin). For a
subgroup of 14 M-TDLN, the matched primary tumour samples were also available
(allowing comparative analysis). An additional group of TDLN included 51
metastatic SLNs (M-SLNs) and 22 NM-SLNs from breast cancer patients. Finally,
13 lymph nodes containing benign salivary gland epithelial inclusions were also
analysed.
Tissue microarray preparation. Three tissue microarray (TMA) blocks were
prepared from a series of 126 PCs from different sites, as detailed in Supplementary
Table S1. TMAs were constructed using an automated tissue microarrayer
(TMA Master, 3DHistech). Three representative tumour areas were identiﬁed on
haematoxylin and eosin (H&E)-stained sections. For each area, a 1mm core was
obtained by punching the original tissue block. Four-micron thick tissue sections
were H&E stained and checked for tumour cell content. Sections and stainings on
TMA were performed as described below. For scoring and panel preparation,
stained sections were digitalized by using the Aperio Scanscope System. Digital
Images were taken as snapshots by using Imagescope software and resized by using
Adobe Photoshop.
Immunohistochemistry and immunoﬂuorescence. Four-micron thick tissue
sections were used for immunohistochemical staining. slanDCs were identiﬁed by
using primary antibodies towards 6-sulfo LacNAc residue (slan/M-DC8) on
PSGL-1, namely clones DD1 and DD2, as previously reported13. The reaction was
revealed using Novolink Polymer (Leica Microsystems) followed by DAB. For
double immunohistochemistry, DD2 was coupled with a panel of markers
(Supplementary Table S5). Brieﬂy, after completing the ﬁrst immune reaction,
the second was visualized using Mach 4 MR-AP (Biocare Medical), followed by
Ferangi Blue (Biocare Medical) as chromogen. For immunoﬂuorescence, DD1 or
DD2 were used in combination with CD11c, CD68, S100 protein and CD3
(see Supplementary Table S5 for detection system and antibody dilutions), and
then sections were counterstained with 40 ,6-diamidino-2-phenylindole. slanDC
interactions were analysed by capturing at least three high power ﬁelds/M-TDLN,
on double-stained sections. The Th-type polarization was deﬁned by automatic cell
counting of positive cells on digitalized slides (Aperio Scanscope, IHC Nuclear
algorithm) obtained from serial sections immunostained, respectively, for GATA3,
T-Bet and Foxp3. Selection of the T-cell area in slanDC-containing M-TDLN was
based on the occurrence of slanDCs, as proved by DD1 stain on serial sections. All
isotype control stains are reported in Supplementary Fig. S10.
Cell isolation and culture. PBMC were isolated under endotoxin-free conditions49
from the whole blood of healthy donors and 22 patients bearing colon
adenocarcinoma (see Supplementary Table S4 for clinical details). slanDCs,
CD1cþ DCs, pDCs and CD14þ monocytes were isolated either from buffy coats
of healthy donors and/or from the blood of CCR patients using speciﬁc isolation
kits from Miltenyi Biotec, according to the manufacturer’s instructions. In the case
of CD4þ T or pan T lymphocytes, cells were isolated from PBMC using,
respectively, the EasySep Human CD4þ T Cell Enrichment Kit (StemCell
Technologies) and the Human Pan T Cell Isolation Kit II (Miltenyi Biotec, Bergisch
Gladbach, Germany). After isolation, cells were suspended in standard medium
(RPMI 1640 medium supplemented with 10% low-endotoxin fetal bovine serum
(o0.5 endotoxin unitsml 1 Lonza, Basel, Switzerland)) and were either
immediately analysed after isolation for antigen expression or cultured up to 18 h
in 48-/96-well tissue culture plates for functional assays (see below). Tonsils,
obtained from patients affected by hypertrophic tonsils or recurrent, chronic
tonsillitis and thus undergoing surgery via cold steel dissection, were minced into
small fragments, treated for 15min at 37 C with 0.2mgml 1 Liberase Blendzyme
2 (Roche, Basel, Switzerland), and processed by gentleMACS dissociator (Miltenyi
Biotec), according to the manufacturer’s instructions. Tonsil cell suspensions were
then washed, ﬁltered through a 40 mm cell strainer and enriched in DCs fraction by
depleting T and B lymphocytes with CD3 and CD19 MicroBeads (Miltenyi Biotec).
All experimental procedures were approved by the institutional review boards of
the University of Verona and Spedali Civili of Brescia. All human samples were
obtained following patients’ informed written consent.
Cell lines. Five (mycoplasma-negative) human colon adenocarcinoma cell lines
were used in this study, namely the SW480-primary and SW620-matched lymph
node metastatic cell lines (from ICLC, National Institute for Cancer Research,
Genoa, Italy), the COLO-678-metastatic cell line (from DSMZ, Braunschweig,
Germany), the HT-29-primary and the LOVO-lymph node metastatic cell lines
(kindly provided by Dr Claudio Sorio, Department of Pathology and Diagnostics,
University of Verona, Italy). Cell lines were cultured in Dulbecco’s Modiﬁed Eagle
Medium supplemented with 10% FBS, with the exception of SW480 cells (cultured
in standard medium). Human umbilical vein endothelial cells were grown on
ﬁbronectin-coated ﬂasks using the EGM-2 Bullet Kit (Lonza).
Flow cytometry. For phenotypic studies by ﬂow cytometry, usually 250,000 PBMC
or 100,000 cells from tonsil suspensions were ﬁrst incubated for 5min in 50 ml PBS
containing 5% human serum (to prevent nonspeciﬁc binding), and then stained for
15min at room T using the monoclonal antibodies listed in Supplementary
Table S6, which also speciﬁes their working dilution. Sample ﬂuorescence was
measured by a seven-colour MACSQuant Analyzer (Miltenyi) or a six-colour
FACSCanto II (BD Biosciences, Franklin Lakes, NJ). Data analysis was performed
by FlowJo software Version 8.8.6 (TreeStar). Phenotypic cell analysis under the
various experimental conditions was performed in live cells, identiﬁed as either
Vybrant DyeCycle Violet- or propidium iodide-negative cells (Life Technologies,
Carlsbad, CA).
Count of peripheral blood DCs. To count the absolute number of circulating
slanDCs and pDCs, 50 ml of whole blood from healthy donors and cancer-bearing
patients were stained for 15min at room T with brilliant violet 510 anti-human
CD45, APC-Cy7 anti-human HLA-DR, PE-Cy7 anti-human CD56/CD3/CD19
(LIN), PerCP-Cy5.5 anti-human CD16, PE anti-human CD123 and FITC anti-
human CD303 or M-DC8 mAbs, at the working dilution speciﬁed in
Supplementary Table S6. Samples were then incubated for 10min with RBC Lysis
Solution (Qiagen, Venlo, Limburg, Netherlands), washed and analysed by
MACSQuant Analyzer (Miltenyi Biotec). slanDCs and pDCs were identiﬁed,
respectively, as HLA-DRþ /CD16þ /M-DC8þ and HLA-DRþ /CD123þ /CD303þ
cells within the CD45þ /LIN cells. The absolute number of DCs per ml was
calculated by multiplying the hemocytometer white blood cell count (performed
independently on whole-blood samples) to the DC percentage among the
CD45hi-gated cells.
Analysis of cytokine production. PBMC were tested for IL-12p70, TNFa and
IFNa production by speciﬁc cytokine secretion assays (Miltenyi Biotec)17. Brieﬂy,
500,000 PBMC isolated from both healthy donors and colorectal cancer-bearing
patients were incubated with 100 ngml 1 LPS (Ultra-Pure E. coli LPS (0111:B4
strain) from Alexis Biochemicals, San Diego, CA) for 4 h at 37 C in standard
medium to optimally detect TNFa. Alternatively, PBMC were ﬁrst cultured for 6 h
and then stimulated for additional 12 h with either 100 ngml 1 LPS plus
100Uml 1 IFNg (R&D Systems), or 5 mgml 1 CpG oligonucleotides type A
(ODN-2216 from InvivoGen, San Diego, CA), to optimally detect IL-12p70 and
IFNa, respectively. slanDC- or pDC-producing cytokines were identiﬁed by
MDC-8- or CD303-positivity, once analysed by MACSQuant Analyzer (Miltenyi
Biotec).
Immunoblots. Whole-cell extracts prepared from both freshly isolated slanDCs
and human umbilical vein endothelial cells by the RNeasy mini kit (Qiagen)50 were
processed for immunoblotting using two different anti-Tie2 Abs (C-20, a mAb
from Santa Cruz Biotechnology, at 1:200 dilution and 0.2 mgml 1 goat polyclonal
Ab from R&D Systems). An anti-b-actin mAb (Sigma, St Louis, Missouri, at
1:2,000 dilution) was also used to check for equal protein loading. Blotted proteins
were quantiﬁed by Odyssey infrared imaging system (LI-COR Biosciences, Lincoln,
Nebraska).
Quantitative RT–PCR. Real time quantitative polymerase chain reaction was
performed as described51 using the following primer pairs (Invitrogen): forward
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50-CTGTTAAAGTTCTTCCAAAGCC-30 and reverse 50-CATATTCTGTCCGAG
GTTCCA-30 for Tie2; forward 50-AGGGTTCGTAGAAGATTCAAGG-30 and
reverse 50-GGAAACATTGTGAGCGATCTC-30 for RPL32. Data were calculated
by Q-Gene software (http://www.gene-quantiﬁcation.de/download.html#qgene)
and expressed as mean normalized expression units after RPL32 normalization.
Chemotaxis assay. Chemotactic assays were performed as described by Hansel
et al.14, with minor modiﬁcations. Brieﬂy, 75 ml of PBMC suspensions (7 106 cells
per ml) in RPMI medium containing 10% FBS were seeded into the upper transwell
inserts (5-mm pore ﬁlter) of a 96-well chemotaxis chamber. 10 ngml 1 C5a,
CXCL12/SDF-1 (R&D Systems) or CX3CL1/Fractalkine (Peprotech, Rocky Hill, NJ)
were added to the bottom wells and, after 1.5 h, transmigrated cells were stained
with CD16 and M- DC8 mAbs (for slanDC identiﬁcation) and quantiﬁed by ﬂow
cytometry. Migration is given as migrated slanDCs, calculated as percentages of
input (slanDCs initially present in the PBMC cell suspension).
Apoptotic cell uptake assay. Puriﬁed slanDCs, CD1cþ DCs, pDCs and CD14þ
monocytes were plated for 18 h in U-bottom 96-well plates in the presence of
apoptotic bodies previously prepared from tumour cell lines, as follows. Tumour
cell lines were cultured under adherent conditions in 24-well plates and, once
conﬂuent, labelled with 5 mM CellTracker Green CMFDA (Molecular Probes).
Cells were then washed, irradiated and cultured under serum-free conditions. After
24 h, non-adherent dead cells were collected (being, on average, 45% apoptotic and
55% necrotic, as assessed by Violet Chromatin Condensation/Dead Cell Apoptosis
Kit (Invitrogen)), washed, counted and ﬁnally added to 2.5 104 slanDCs from
healthy donors or CCR patients, or to CD1cþ DCs, pDCs and CD14þ monocytes
from healthy donors at a 1/1-1/3 ratio (DCs/dead cells) for 15 h at both 37 C and
at 4 C. The latter condition was used to determine the basal % of phagocytosing
DCs/monocytes (alwaysr5%). Plates were then centrifuged at 300 g for 10min,
medium removed and cells suspended in HBSS buffer containing 1 mM VybrantTM
DyeCycleTM Violet stain (Molecular Probes, Eugene, Oregon) and HLA-DR
APC- Cy7 for 30min on ice. Phagocytosing cells were deﬁned, by ﬂow cytometry,
as those cells that resulted CMFDA green ﬂuorescence-positive among the
Vybrant /HLA-DRþ cells (live DCs/monocytes).
T-cell proliferation assay. Freshly isolated slanDCs (5 103) from both healthy
donors and CCR patients were co-cultured either with 5 104 CFSE-labelled
autologous CD4þ T lymphocytes, in the absence or presence of 5 mgml 1 tetanus
toxoid15, or with 5 104 CFSE-labelled allogeneic pan T lymphocytes in
U-bottomed 96-well plates (Costar, Corning Incorporated, Corning, NY). Under
the latter experimental conditions, CD4þ and CD8þ T-cell populations were
identiﬁed, respectively, as CD3þ /CD4þ and CD3þ /CD8þ cells, by ﬂow
cytometry. T-cell proliferation was assessed by CFSE dilution on day 7.
Statistical analysis. Data are expressed as mean±s.d. of the number of experi-
ments indicated in each ﬁgure legend. Statistical analysis, including two-tailed
Student’s t-test, Fisher test, one-way or two-way analysis of variance was performed
by Prism Version 4.0 software (GraphPad).
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